Abbott and Medtronic Announce Global Partnership to Integrate FreeStyle Libre CGM Technology into Medtronic Insulin Delivery Systems

August 17, 2026

Abbott (via Facebook press release), Medtronic USA

Overview

Medtronic and Abbott have announced a global partnership to integrate Abbott’s FreeStyle Libre sensing technology into Medtronic’s insulin delivery systems. Under this agreement, Abbott will develop dedicated CGM sensors for Medtronic devices, which Medtronic will exclusively commercialize. This collaboration aims to provide diabetes patients with more CGM options and a seamless experience between their insulin delivery systems and glucose monitoring, simplifying diabetes management and enhancing both companies’ competitiveness in the global diabetes care market.

In Depth

Key Findings

Medtronic and Abbott have announced a global partnership to integrate Abbott’s leading continuous glucose monitoring (CGM) technology, FreeStyle Libre, into Medtronic’s insulin delivery systems. This strategic alliance is designed to offer diabetes patients a broader range of CGM options and a more seamless integration with their insulin therapy regimens.

Technical/Clinical Details

As part of this collaboration, Abbott will develop a custom CGM sensor specifically for Medtronic’s automated insulin delivery (AID) systems and smart pen platforms. This specialized sensor will leverage the advanced sensing capabilities of Abbott’s FreeStyle Libre platform, enabling direct communication with Medtronic’s devices to provide real-time glucose data. Patients utilizing Medtronic’s insulin pumps or smart pens will consequently be able to adjust their insulin dosages more accurately based on comprehensive CGM data. This is expected to optimize glycemic control and mitigate the risks of hypoglycemia and hyperglycemia. Medtronic’s exclusive commercialization rights for this Abbott-developed CGM sensor are anticipated to streamline its market introduction and adoption.

Background & Context

CGM systems have become indispensable tools in diabetes management, providing crucial insights into glucose trends that facilitate more effective treatment planning. The synergy between insulin pumps/smart pens and CGM is particularly valuable, as it reduces the manual burden of insulin adjustments for patients and enables a more personalized, automated approach to care. Historically, individual CGM and insulin delivery device manufacturers have developed proprietary systems, leading to interoperability challenges. This partnership between Abbott and Medtronic, two major players in the industry, is significant for overcoming these hurdles and advancing patient-centric diabetes care. The move reflects an industry-wide trend toward building integrated device ecosystems that enhance patient choice and convenience.

Strategic Significance & Outlook

This global partnership is poised to significantly impact the worldwide diabetes care market. Abbott stands to expand its reach within the CGM sector, while Medtronic can enhance the appeal of its insulin delivery systems by offering highly sought-after CGM options. The combined strengths of both companies promise to deliver more integrated, user-friendly solutions for diabetes patients, which should lead to improved treatment adherence and an overall enhancement in quality of life. In the future, such collaborations are expected to further catalyze the integration with other digital health technologies, accelerating the formation of comprehensive diabetes management ecosystems.

Source: #

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.